[1] |
Möller, H.J. Long-acting risperidone: Focus on safety. Clin. Ther. 2006, 28, 633–651.
|
[2] |
Ascher-Svanum, H.; Montgomery, B.; McDonnell, Coleman, Feldman, P.D. Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons. Int. J. Gen. Med. 2012, 391.
|
[3] |
Valenstein, M.; Ganoczy, D.; McCarthy, J.F.; Kim, H.M.; Lee, T.A.; Blow, F.C. Antipsychotic adherence over time among patients receiving treatment for schizophrenia. J. Clin. Psychiatry. 2006, 67, 1542–1550.
|
[4] |
Kane, J.M. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J. Clin. Psychiatry. 2003, 64, 34–40.
|
[5] |
McEvoy, J.P. Risks versus benefits of different types of long-acting injectable antipsychotics. J. Clin. Psychiatry. 2006, 67, 15–18.
|
[6] |
Gray, R.; Spilling, R.; Burgess, D.; Newey, T. Antipsychotic long-acting injections in clinical practice: Medication management and patient choice. Br. J. Psychiatry. 2009, 195, s51–s56.
|
[7] |
Chang, C.L.; Tzeng, D.S.; Lung, F.W. Treatment effectiveness and adherence in patients with schizophrenia treated with risperidone long-acting injection. Psychiatry Res. 2010, 180, 16–19.
|
[8] |
Nielsen, J.; Jensen, S.O.W.; Friis, R.B.; Valentin, J.B.; Correll, C.U. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study. Schizophr. Bull. 2015, 41, 627–636.
|
[9] |
Meltzer, H.Y.; Lindenmayer, J.P.; Kwentus, J.; Share, D.B.; Johnson, R.; Jayathilake, K. A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia. Schizophr. Res. 2014, 154, 14–22.
|
[10] |
Eerdekens, M.; van Hove, I.; Remmerie, B.; Mannaert, E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr. Res. 2004, 70, 91–100.
|
[11] |
Thyssen, A.; Rusch, S.; Herben, V.; Quiroz, J.; Mannaert, E. Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients. J. Clin. Pharmacol. 2010, 50, 1011–1021.
|
[12] |
RISPERDAL® CONSTA® (risperidone) LONG-ACTING INJECTION introduction. Janssen Pharmaceuticals, Inc. 2007.
|
[13] |
Gharabawi, G.M.; Gearhart, N.C.; Lasser, R.A.; Mahmoud, R.A.; Zhu, Y.; Mannaert, E.; Naessens, I.; Bossie, C.A.; Kujawa, M.; Simpson, G.M. Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval. Ann. Gen. Psychiatry. 2007, 6, 3.
|
[14] |
Keks, N.A.; Ingham, M.; Khan, A.; Karcher, K. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Br. J. Psychiatry. 2007, 191, 131–139.
|
[15] |
Pandina, G.; Lane, R.; Gopal, S.; Gassmann-Mayer, C.; Hough, D.; Remmerie, B.; Simpson, G. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2011, 35, 218–226.
|
[16] |
de Meulder, M.; Remmerie, B.M.M.; de Vries, R.; Sips, L.L.A.; Boom, S.; Hooijschuur, E.W.J.; van de Merbel, N.C.; Timmerman, P.M.M.B.L. Validated LC-MS/MS methods for the determination of risperidone and the enantiomers of 9-hydroxyrisperidone in human plasma and urine. J. Chromatogr. B. 2008, 870, 8–16.
|
[17] |
Cabovska, B.; Cox, S.L.; Vinks, A.A. Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS/MS. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2007, 852, 497–504.
|
[18] |
Chou, W.H.; Yan, F.X.; Robbins-Weilert, D.K.; Ryder, T.B.; Liu, W.W.; Perbost, C.; Fairchild, M.; de Leon, J.; Koch, W.H.; Wedlund, P.J. Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin. Chem. 2003, 49, 542–551.
|
[19] |
Pandina, G.; Kushner, S.; Karcher, K.; Haas, M. An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia. Child Adolesc. Psychiatry Ment. Heal. 2012, 6, 23.
|
[20] |
Calarge, C.A.; Acion, L.; Kuperman, S.; Tansey, M.; Schlechte, J.A. Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. J. Child Adolesc. Psychopharmacol. 2009, 19, 101–109.
|
[21] |
Spina, E.; Avenoso, A.; Facciolà, G.; Salemi, M.; Scordo, M.G.; Ancione, M.; Madia, A.G.; Perucca, E. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology. 2001, 153, 238–243.
|
[22] |
Wang, L.; Yu, L.; Zhang, A.P.; Fang, C.; Du, J.; Gu, N.F.; Qin, S.Y.; Feng, G.Y.; Li, X.W.; Xing, Q.H.; He, L. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia. J. Psychopharmacol. Oxf. Engl. 2007, 21, 837–842.
|